Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$123.78
+5.7%
$117.02
$5.59
$148.83
$9.81B0.841.11 million shs1.27 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$101.47
-1.1%
$101.94
$63.56
$113.01
$7.98B1.15566,872 shs612,503 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$56.24
+2.9%
$53.86
$18.89
$60.08
$2.28B0.61272,883 shs185,402 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$55.60
-4.9%
$58.73
$28.09
$65.00
$8.03B1.31.34 million shs2.17 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
0.00%+5.10%-0.64%+3.79%+1,535.74%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
0.00%-4.81%-6.06%-7.59%+27.86%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%-2.23%-1.13%+32.87%+181.78%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%-4.67%-2.48%+2.15%+60.86%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$123.78
+5.7%
$117.02
$5.59
$148.83
$9.81B0.841.11 million shs1.27 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$101.47
-1.1%
$101.94
$63.56
$113.01
$7.98B1.15566,872 shs612,503 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$56.24
+2.9%
$53.86
$18.89
$60.08
$2.28B0.61272,883 shs185,402 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$55.60
-4.9%
$58.73
$28.09
$65.00
$8.03B1.31.34 million shs2.17 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
0.00%+5.10%-0.64%+3.79%+1,535.74%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
0.00%-4.81%-6.06%-7.59%+27.86%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%-2.23%-1.13%+32.87%+181.78%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
0.00%-4.67%-2.48%+2.15%+60.86%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.93
Moderate Buy$137.1510.80% Upside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
2.88
Moderate Buy$137.2535.26% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.43
Hold$42.40-24.61% Downside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.63
Moderate Buy$86.0054.69% Upside

Current Analyst Ratings Breakdown

Latest PAHC, ABVX, PCVX, and NUVL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Reiterated RatingSell (D-)
4/21/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Reiterated RatingBuy$155.00
4/20/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingSell (D-)
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageNeutral$62.00
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageHold$62.00
4/9/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingOutperform
4/8/2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Reiterated RatingSell (D-)
4/8/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Reiterated RatingOutperform$125.00
3/30/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Initiated CoverageOverweight$116.00
3/24/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Boost Price TargetOverweight$142.00 ➝ $148.00
3/16/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Initiated CoverageBuy$160.00
(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$15.95 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.46B1.56$3.35 per share16.79$7.05 per share7.98
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$20.51 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$5.37N/AN/AN/AN/A-146.43%-88.69%5/25/2026 (Estimated)
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$425.38M-$5.85N/AN/AN/AN/A-39.29%-35.01%5/7/2026 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.2525.0017.150.846.29%38.28%8.37%5/6/2026 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$5.62N/AN/AN/AN/A-25.88%-23.85%5/6/2026 (Estimated)

Latest PAHC, ABVX, PCVX, and NUVL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/25/2026Q1 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9360N/AN/AN/A$0.40 millionN/A
5/7/2026Q1 2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.35N/AN/AN/A$0.49 millionN/A
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72N/AN/AN/A$367.02 millionN/A
5/6/2026Q1 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.7411N/AN/AN/A$12.50 millionN/A
3/23/2026Q4 2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 million
2/24/2026Q4 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.46-$1.80-$0.34-$1.80$18.75 millionN/A
2/14/2026Q4 2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A-$1.20N/A-$1.20N/A$0.52 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.480.85%N/A21.33%N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
8.75
8.75
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
15.27
15.27
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.14
3.05
1.22
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
7.91
7.91

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10.20%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6179.29 millionN/ANot Optionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4078.62 million70.60 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.54 million20.22 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160144.39 million139.91 millionOptionable

Recent News About These Companies

Vaxcyte (NASDAQ:PCVX) Cut to "Strong Sell" at Wall Street Zen
5 Best 52-Week High US Stocks to Buy
Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abivax stock logo

Abivax NASDAQ:ABVX

$123.78 +6.65 (+5.68%)
Closing price 04:00 PM Eastern
Extended Trading
$123.71 -0.07 (-0.05%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$101.47 -1.15 (-1.12%)
Closing price 04:00 PM Eastern
Extended Trading
$101.45 -0.02 (-0.02%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$56.24 +1.56 (+2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$56.33 +0.09 (+0.16%)
As of 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$55.60 -2.89 (-4.95%)
Closing price 03:59 PM Eastern
Extended Trading
$55.52 -0.08 (-0.15%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.